Evidence map›Paper›PMID 35658906›Full record

ArticleBMC ophthalmology2022

Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema.

Taro Otawa, Hidetaka Noma, Kanako Yasuda, Akitomo Narimatsu, Masaki Asakage, Akina Tanaka, Hiroshi Goto, Masahiko Shimura

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Taro OtawaDepartment of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, Tatemachi, 1163, 193-0998, Hachioji, Tokyo, Japan.
Hidetaka NomaDepartment of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, Tatemachi, 1163, 193-0998, Hachioji, Tokyo, Japan. nomahide1122@gmail.com.
Kanako YasudaDepartment of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, Tatemachi, 1163, 193-0998, Hachioji, Tokyo, Japan.
Akitomo NarimatsuDepartment of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, Tatemachi, 1163, 193-0998, Hachioji, Tokyo, Japan.
Masaki AsakageDepartment of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, Tatemachi, 1163, 193-0998, Hachioji, Tokyo, Japan.
Akina TanakaDepartment of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, Tatemachi, 1163, 193-0998, Hachioji, Tokyo, Japan.
Hiroshi GotoDepartment of Ophthalmology, Tokyo Medical University, Tokyo, Japan.
Masahiko ShimuraDepartment of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, Tatemachi, 1163, 193-0998, Hachioji, Tokyo, Japan.
Tokyo Medical University Hachioji Medical Center · JPTokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with central retinal vein occlusion (CRVO) and macular edema often are treated by intravitreal ranibizumab injection (IRI). The role of changes in macular sensitivity in the positive effects of IRI on visual functions is unclear. Therefore, we assessed the relationship between macular sensitivity and improvement of visual functions.

methodsWe included 15 eyes of 15 patients with treatment-naïve CRVO and followed patients for 6 months after pro re nata IRI. IRI was repeated if the central macular thickness was greater than or equal to 300 µm. Microperimetry-3 was used to measure macular sensitivity within the central 1-mm, 3-mm, and 6-mm fields before and monthly for 6 months after IRI.

resultsIRI significantly improved mean macular sensitivity over time within the central 1-mm, 3-mm, and 6-mm fields (all P < 0.001). None of the fields showed significant differences in the change of mean macular sensitivity between patients with little improvement in best corrected visual acuity (BCVA; i.e., in patients with a change in logarithm of the minimum angle of resolution [logMAR] BCVA < 0.3) and those with marked improvement in BCVA (change in logMAR BCVA > 0.3). The mean macular sensitivity before IRI showed correlations with the improvement of macular sensitivity in every field.

conclusionThese findings suggest that IRI improves macular sensitivity in patients with CRVO and macular edema independent of any improvement in BCVA and that macular sensitivity before treatment is associated with improvement of macular sensitivity after treatment.

Indexed as

Macular EdemaRetinal Vein OcclusionAngiogenesis InhibitorsEdemaHumansIntravitreal InjectionsRanibizumabTomography, Optical CoherenceTreatment OutcomeVisual AcuityAngiogenesis InhibitorsRanibizumabCentral retinal vein occlusionMacular edemaMacular sensitivityRanibizumab

Identifiers

PMID35658906
PMCPMC9166445
OpenAlexW4281664543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.